AIC-100

N/A

Report date: 2025/07/10 11:35:53

Base Information

Drug NameAIC-100
Drug Alias NameMicromolar affinity tuned CAR T-cellsAIC-100
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAnti-Intercellular adhesion molecule-1
TargetsIntercellular adhesion molecule-1
Therapy Area/IndicationsOncocytic cell carcinoma of the thyroidThyroid Carcinoma, Anaplastic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAffyimmune Therapeutics IncNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesAffyimmune Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsOncocytic cell carcinoma of the thyroidThyroid Carcinoma, Anaplastic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A